Tags: Chemical Compound, Chemical Substance.
TH-302 is an experimental cancer treatment that is in clinical development at Threshold Pharmaceuticals Inc. It is activated only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors a phenomenon known as tumor hypoxia. TH-302 exploits the activation of a nitroazole prodrug by a process that involves a one electron reduction mediated by ubiquitous cellular reductases such as the NADPH cytochrome P450 to generate a radical anion prodrug (RP).
